Five-year clinical outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer.

Autor: Seo KW; Department of Cardiology, Ajou University School of Medicine, Suwon., Yang HM; Department of Cardiology, Ajou University School of Medicine, Suwon., Yoon J; Department of Cardiology, Yonsei University Wonju Christian Hospital, Wonju., Kim HS; Department of Internal Medicine, Seoul National University College of Medicine., Chang K; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Lim HS; Department of Cardiology, Ajou University School of Medicine, Suwon., Choi BJ; Department of Cardiology, Ajou University School of Medicine, Suwon., Choi SY; Department of Cardiology, Ajou University School of Medicine, Suwon., Yoon MH; Department of Cardiology, Ajou University School of Medicine, Suwon., Lee SH; Department of Cardiology, Yonsei University Wonju Christian Hospital, Wonju., Ahn SG; Department of Cardiology, Yonsei University Wonju Christian Hospital, Wonju., Youn YJ; Department of Cardiology, Yonsei University Wonju Christian Hospital, Wonju., Lee JW; Department of Cardiology, Yonsei University Wonju Christian Hospital, Wonju., Koo BK; Department of Internal Medicine, Seoul National University College of Medicine., Park KW; Department of Internal Medicine, Seoul National University College of Medicine., Yang HM; Department of Internal Medicine, Seoul National University College of Medicine., Han JK; Department of Internal Medicine, Seoul National University College of Medicine., Chung WS; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Park HJ; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Hwang BH; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Choo EH; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Oh GC; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Tahk SJ; Department of Cardiology, Ajou University School of Medicine, Suwon.
Jazyk: angličtina
Zdroj: Medicine [Medicine (Baltimore)] 2021 May 14; Vol. 100 (19), pp. e25765.
DOI: 10.1097/MD.0000000000025765
Abstrakt: Abstract: This study evaluated the 5-year clinical outcomes of the Genoss DES, the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer.We previously conducted the first-in-patient prospective, multicenter, randomized trial with a 1:1 ratio of patients using the Genoss DES and Promus Element stents; the angiographic and clinical outcomes of the Genoss DES stent were comparable to those of the Promus Element stent. The primary endpoint was major adverse cardiac events (MACE), which was a composite of death, myocardial infarction (MI), and target lesion revascularization (TLR) at 5 years.We enrolled 38 patients in the Genoss DES group and 39 in the Promus Element group. Thirty-eight patients (100%) from the Genoss DES group and 38 (97.4%) from the Promus Element group were followed up at 5 years. The rates of MACE (5.3% vs 12.8%, P = .431), death (5.3% vs 10.3%, P = .675), TLR (2.6% vs 2.6%, P = 1.000), and target vessel revascularization (TVR) (7.9% vs 2.6%, P = .358) at 5 years did not differ significantly between the groups. No TLR or target vessel revascularization was reported from years 1 to 5 after the index procedure, and no MI or stent thrombosis occurred in either group during 5 years.The biodegradable polymer Genoss DES and durable polymer Promus Element stents showed comparable low rates of MACE at the 5-year clinical follow-up.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze: MEDLINE